21 de octubre de 2019
22 de enero de 2009

New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis


References
1. Schäfer T. Epidemiology of Psoriasis; Review and the German
Perspective. Dermatology. 2006;212:327-337.
2. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives
on the impact of psoriasis: the EUROPSO patient membership survey. Br
J Dermatol. 2006;155(4):729-736.
3. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am
Acad Dermatol. 1995;32(6):982-986.
4. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of
ustekinumab, a human interleukin-12/23 monoclonal antibody, in
patients with psoriasis: 76-week results from a randomised,
double-blind, placebo-controlled trial (PHOENIX 1). The Lancet.
2008;371:1665-74.
5. Papp K, Langley RG, Lebwohl M, et al. Efficacy and safety of
ustekinumab, a human interleukin-12/23 monoclonal antibody, in
patients with psoriasis: 52-week results from a randomised,
double-blind, placebo-controlled trial (PHOENIX 2). The Lancet.
2008;371:1675-84.
6. Smith CH, Anstey AV, Barker JN, et al. British Association of
Dermatologists guidelines for use of biological interventions in
Psoriasis 2005. Br J Dermatol. 2005;153(3):486-497.

For further information, please contact: Jennifer Tear, Janssen Cilag, Turnhoutsweg 30, Beerse 2340, Belgium. Tel: +32-14-60-26-38, Mobile +32-473-55-94-60, Email JTear1@its.jnj.com . Media Investors: Tina Pinto, Johnson & Johnson, Phone: +1-732-524-2034.